Skip to content

The Effect of Vitamin D Replacement on Airway Reactivity, Allergy and Inflammatory Mediators in Exhaled Breath Condensate in Vitamin D Deficient Asthmatic Children

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01287455
Enrollment
83
Registered
2011-02-01
Start date
2011-02-28
Completion date
2012-12-31
Last updated
2013-06-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma, Vitamin D Deficiency

Keywords

Asthma, Vitamin D, airway reactivity, metacholine challenge test

Brief summary

Research Title: The effect of vitamin D replacement on airway reactivity, allergy and inflammatory mediators in exhaled breath condensate in vitamin D deficient asthmatic children. Introduction: Vitamin D seems to play a role in allergic and asthmatic reactions as an immunomodulator. Asthma disease involves inflammatory process in the lower respiratory tract and airway hyperreactivity. Aim: To assess the effect of Vitamin D replacement on airway reactivity, and allergy and inflammatory mediators in exhaled breath condensate in vitamin D deficient asthmatic children. Design: Double blind placebo control prospective study comparing the effect of Vitamin D replacement and placebo on airway reactivity, allergy and inflammatory mediators in exhaled breath condensate in asthmatic pediatric population with vitamin D deficiency. Participant selection: The study group will consist of pediatric patients (age 6-18 years) followed and treated at the Pediatric Pulmonary Unit at the investigators hospital. Patients with mild-moderate asthma with low or insufficient vitamin D levels that are currently not receiving anti-inflammatory treatment will be recruited. Sample size: 60 participants in the two groups (30 receiving Vitamin D and 30 receiving placebo). Intervention: Vitamin D (14000 units) or placebo will be provided in a similar appearance preparation once weekly for 6 weeks between visit two and three. Three visits will be conducted. Each subject will undergo evaluation including a respiratory questionnaire (visit 1), methacholine challenge test with determination of PC20 (visit 1 or 2 and visit 3), exhaled nitric oxide (eNO) (visit 2, 3), and exhaled breath condensate (EBC) (visit 2,3). Venous blood will be analyzed for complete blood count + eosinophils (visit 1, 3), IGE levels (visit 1, 3), and Vitamin D levels (visit 1, 3). Prick skin test for inhaled allergens will be performed (visit 2, 3). Primary end point: Airway reactivity as assessed by methacholine challenge test. Secondary outcome parameters: All other parameters are the secondary end points.

Interventions

DRUGVitamin D3 as BABY D3

drops, 70 drops (= 14000 units), once weekly for 6 weeks

OTHERplacebo

drops, 70 placebo drops, once weekly for 6 weeks

Sponsors

Rambam Health Care Campus
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Masking
TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender
ALL
Age
6 Years to 18 Years
Healthy volunteers
No

Inclusion criteria

* 6-18 years * Mild-moderate asthma * No anti inflammatory treatment over the past 2 weeks

Exclusion criteria

* Any Chronic Lung Disease * Febrile Illness in last 2 weeks * FEV1 \< 65% in study day * Bronchodilators over the past 24 hours prior to each study * Participation in any other clinical studies over the past 4 weeks

Design outcomes

Primary

MeasureTime frameDescription
Metacholine Challenge Teststudy visit 1,3 (6wks- 3 months)As assessed by methacholine challenge test with determination of PC20.

Secondary

MeasureTime frameDescription
IGEstudy visit 1,3 (6wks- 3 months)in peripheral Blood count
CBCstudy visit 1,3 (6wks- 3 months)in peripheral Blood count
Fractional Exhaled NOvisit study 2,3 (6wks)determination of exhaled NO in Exhaled breath
skin tests for inhaled allergensvisit study 2,3 (6wks)
Exhaled breath condensatevisit study 2,3 (6wks)R-tubes test

Countries

Israel

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 5, 2026